Brainstorm Cell Therapeutics (BCLI) Misses Q3 EPS by 176c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($1.80), $1.76 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim
• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance
• Barclays sees global expansion intact, warns against market complacency